Contextual immersion trading strategy idea. Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next...
They have an upside price target of 5.40. There a few resistance points but I will probably set my long term target at the top green marker on the chart. A downfall from time to time is the volume on this stock. Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for...
This would could be 60-120% gianer if you get in correctly. I am waiting maybe tomorrow or day just depends. I want to know we have a bottom here. LONG.
Historical support at 2 dollars. I’m anticipating a bounce.
Positive news today "CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma". This stock Shs Float is 5.15M, and Market Cap 14.76M.
CLRB has a buy rating on Zacks Rank, but it has poor financial. Based on my experience (or lack of) studying the graph, I expect the stock will drop in the future. At the moment the stock is $4.08.
FDA approval this morning MACD curling
Waiting for Phase 2 data to restart the hype for this low floater.
Very interesting to see this stock bottom, breakout, and GAP fill in 1 trading session.
small cloud but in relative strength strong new hot industry see our book on amazon for selecting stockdsin strong groups cmf increasing should pass cloud soon good volume long narrow base